openPR Logo
Press release

United States Herceptin Biosimilar Market 2017

07-03-2017 04:07 PM CET | Health & Medicine

Press release from: Global QYResearch

Global QYResearch

Global QYResearch

In this report, the United States Herceptin Biosimilar Market 2017 is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
The West
Southwest
The Middle Atlantic
New England
The South
The Midwest
with sales (volume), revenue (value), market share and growth rate of Herceptin Biosimilar in these regions, from 2012 to 2022 (forecast).

United States Herceptin Biosimilar market competition by top manufacturers/players, with Herceptin Biosimilar sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
Mylan
Amgen
Mabion
AryoGen Biopharma
Genor Biopharma
The Instituto Vital Brazil
Celltrion
Gedeon Richter

Request more information at http://globalqyresearch.com/download-sample/232596

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
Capsule
Tablet
Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Herceptin Biosimilar for each application, including
Healthcare&Pharmaceuticals
Others

If you have any special requirements, please let us know and we will offer you the report as you want.

View full report at http://globalqyresearch.com/united-states-herceptin-biosimilar-market-report-2017

Table of Contents

United States Herceptin Biosimilar Market Report 2017
1 Herceptin Biosimilar Overview
1.1 Product Overview and Scope of Herceptin Biosimilar
1.2 Classification of Herceptin Biosimilar by Product Category
1.2.1 United States Herceptin Biosimilar Market Size (Sales Volume) Comparison by Type (2012-2022)
1.2.2 United States Herceptin Biosimilar Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
1.2.3 Capsule
1.2.4 Tablet
1.2.5 Others
1.3 United States Herceptin Biosimilar Market by Application/End Users
1.3.1 United States Herceptin Biosimilar Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
1.3.2 Healthcare&Pharmaceuticals
1.3.3 Others
1.4 United States Herceptin Biosimilar Market by Region
1.4.1 United States Herceptin Biosimilar Market Size (Value) Comparison by Region (2012-2022)
1.4.2 The West Herceptin Biosimilar Status and Prospect (2012-2022)
1.4.3 Southwest Herceptin Biosimilar Status and Prospect (2012-2022)
1.4.4 The Middle Atlantic Herceptin Biosimilar Status and Prospect (2012-2022)
1.4.5 New England Herceptin Biosimilar Status and Prospect (2012-2022)
1.4.6 The South Herceptin Biosimilar Status and Prospect (2012-2022)
1.4.7 The Midwest Herceptin Biosimilar Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Herceptin Biosimilar (2012-2022)
1.5.1 United States Herceptin Biosimilar Sales and Growth Rate (2012-2022)
1.5.2 United States Herceptin Biosimilar Revenue and Growth Rate (2012-2022)

2 United States Herceptin Biosimilar Market Competition by Players/Suppliers
2.1 United States Herceptin Biosimilar Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Herceptin Biosimilar Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Herceptin Biosimilar Average Price by Players/Suppliers (2012-2017)
2.4 United States Herceptin Biosimilar Market Competitive Situation and Trends
2.4.1 United States Herceptin Biosimilar Market Concentration Rate
2.4.2 United States Herceptin Biosimilar Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Herceptin Biosimilar Manufacturing Base Distribution, Sales Area, Product Type

3 United States Herceptin Biosimilar Sales (Volume) and Revenue (Value) by Region (2012-2017)
3.1 United States Herceptin Biosimilar Sales and Market Share by Region (2012-2017)
3.2 United States Herceptin Biosimilar Revenue and Market Share by Region (2012-2017)
3.3 United States Herceptin Biosimilar Price by Region (2012-2017)

4 United States Herceptin Biosimilar Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
4.1 United States Herceptin Biosimilar Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Herceptin Biosimilar Revenue and Market Share by Type (2012-2017)
4.3 United States Herceptin Biosimilar Price by Type (2012-2017)
4.4 United States Herceptin Biosimilar Sales Growth Rate by Type (2012-2017)

5 United States Herceptin Biosimilar Sales (Volume) by Application (2012-2017)
5.1 United States Herceptin Biosimilar Sales and Market Share by Application (2012-2017)
5.2 United States Herceptin Biosimilar Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 United States Herceptin Biosimilar Players/Suppliers Profiles and Sales Data
6.1 Mylan
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Herceptin Biosimilar Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Mylan Herceptin Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Amgen
6.2.2 Herceptin Biosimilar Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Amgen Herceptin Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Mabion
6.3.2 Herceptin Biosimilar Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Mabion Herceptin Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 AryoGen Biopharma
6.4.2 Herceptin Biosimilar Product Category, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 AryoGen Biopharma Herceptin Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 Genor Biopharma
6.5.2 Herceptin Biosimilar Product Category, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Genor Biopharma Herceptin Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
6.6 The Instituto Vital Brazil
6.6.2 Herceptin Biosimilar Product Category, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 The Instituto Vital Brazil Herceptin Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
6.6.4 Main Business/Business Overview
6.7 Celltrion
6.7.2 Herceptin Biosimilar Product Category, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Celltrion Herceptin Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
6.7.4 Main Business/Business Overview
6.8 Gedeon Richter
6.8.2 Herceptin Biosimilar Product Category, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Gedeon Richter Herceptin Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
6.8.4 Main Business/Business Overview

7 Herceptin Biosimilar Manufacturing Cost Analysis
7.1 Herceptin Biosimilar Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Herceptin Biosimilar

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Herceptin Biosimilar Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Herceptin Biosimilar Major Manufacturers in 2016
8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List

10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 United States Herceptin Biosimilar Market Size (Value and Volume) Forecast (2017-2022)
11.1 United States Herceptin Biosimilar Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Herceptin Biosimilar Sales Volume Forecast by Type (2017-2022)
11.3 United States Herceptin Biosimilar Sales Volume Forecast by Application (2017-2022)
11.4 United States Herceptin Biosimilar Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix

To Purchase this premium Report With Complete TOC at http://globalqyresearch.com/checkout-form/0/232596

About Us:

Global QYResearch (http://globalqyresearch.com/) is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.

Contact Us:

Unit1, 26 Cleveland Road, South Woodford, London, E182AN, United Kingdom

Contact: +44 20 32392407

Email: sales@globalqyresearch.com

Follow us:https://www.linkedin.com/company/global-qy-research

Twitter: https://twitter.com/gqyresearch

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release United States Herceptin Biosimilar Market 2017 here

News-ID: 606390 • Views: 295

More Releases from Global QYResearch

Global Hepatitis C Drug Sales Market 2017
In this report, the Global Hepatitis C Drug Market 2017 is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Hepatitis C Drug for these regions, from 2012
Global 8-Methoxypsoralen (298-81-7) Market 2017
In this report, the Global 8-Methoxypsoralen (298-81-7) Market 2017 is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of 8-Methoxypsoralen (298-81-7) in these regions, from 2012 to 2022 (forecast),
Global Aircraft MRO Market Size, Status and Forecast 2022
This report studies the global Aircraft MRO market, analyzes and researches the Aircraft MRO development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Lufthansa Technik GE Aviation AFI KLM E&M ST Aerospace MTU AAR SR Technics (Mubadala) SIA Engineering Delta TechOps Haeco Ameco Beijing Iberia Maintenance ANA JAL Engineering Korean Air KAI Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast Asia Request more information at http://globalqyresearch.com/download-sample/218564 Market segment by Type, Aircraft MRO can
Global Blow Fill Seal (BFS) Technology Market Size, Status and Forecast 2022
This report studies the global Blow Fill Seal (BFS) Technology market, analyzes and researches the Blow Fill Seal (BFS) Technology development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Takeda Pharmaceuticals International Unither Pharmaceuticals Brevetti Angela Unipharma Rommelag Kunststoff-Maschinen Vertriebsgesellschaft Horizon Pharmaceuticals Weiler Engineering Nephron Pharmaceuticals Corporation Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast Asia Request more information at http://globalqyresearch.com/download-sample/212644 Market segment by Type,

All 5 Releases


More Releases for Herceptin

Herceptin Biosimilar Market to Discern Steadfast Expansion During 2029
Global Herceptin Biosimilar Market: Overview Growing number of people living with gastric cancers and metastatic (spread) breast cancer is expected to drive demand opportunities for enterprises working in the global herceptin biosimilar market. Herceptin refers to a monoclonal antibody mainly utilized in the treatment of critical cancers like gastric cancers and metastatic (spread) breast cancer. An upcoming research report on the global herceptin biosimilar market provides a complete analysis of this market.
Herceptin Biosimilar Market: Industry Insights, Challenges, CAGR Analysis and Wo …
This report studies the global market size of Herceptin Biosimilar in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Herceptin Biosimilar in these regions. This research report at InForGrowth categorizes the global Herceptin Biosimilar market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future
Herceptin Biosimilar Industry balanced to Reach Insignificant CAGR till 2023
Worldwide Market Reports added Latest Research Report titled “Global and Chinese Herceptin Biosimilar Industry, 2018 Market Research Report” to its Large Report database. The ‘Global and Chinese Herceptin Biosimilar Industry, 2013-2023 Market Research Report’ is a professional and in-depth study on the current state of the global Herceptin Biosimilar industry with a focus on the Chinese market. The report provides key statistics on the market status of the Herceptin Biosimilar manufacturers
Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight
“Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Herceptin are commercially available in India and Iran for the treatment of Breast cancer. The patent on Herceptin expired in 2014. Trastuzumab or
Global Herceptin Biosimilar Market Research Depth Analysis with Opportunity Asse …
Herceptin Biosimilar Market Research Report Monitor Present's Global Herceptin Biosimilar Market 2017 Industry Trend Enhances The Decision Making Capabilities And Helps To Create An Effective Counter Strategies To Gain Competitive Advantage. Description The Global Herceptin Biosimilar Protein Report Offers A Comprehensive Evaluation Of The Global Herceptin Biosimilar Protein Industry. This Report Evaluates The Global Market For "Global Herceptin Biosimilar Protein". The Global Herceptin Biosimilar Protein Report Provides Complete Analysis Of The Global Herceptin
Global Herceptin Biosimilar Market Research Report 2017
Report Hive Market Research Released a New Research Report of 106 pages on Title " Global Herceptin Biosimilar Market Research Report 2017 "with detailed Analysis, Forecast and Strategies. In this report, the global Herceptin Biosimilar market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented